Sejal H Shah, MD
Pediatric Medicine · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · Lpch Medical Group Div of Lucile · 332 clinicians in this group
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Shah’s office at (650) 498-7200 to ask if they take your plan before you enroll.
California Medical Board record
Licence A103168 · Current
Licensed to practise in California · since 2008 · expires 2027-08-31 · Northwestern University Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Medicaid work
$15,981 in 2024
Medicaid paid $15,981 for 126 billed services this clinician did in 2024, up to 20 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 112 | $13,420 |
| Long return visit (40+ min) | 14 | $2,560 |
| 2024 | 126 | 2 | 20 | $15,981 |
| 2023 | 158 | 2 | 24 | $17,525 |
| 2022 | 177 | 1 | 28 | $16,648 |
| 2021 | 252 | 2 | 25 | $27,414 |
| 2020 | 185 | 2 | 24 | $15,898 |
| 2019 | 196 | 2 | 29 | $19,520 |
| 2018 | 454 | 4 | 48 | $32,012 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 133 | $13,742 |
| Long return visit (40+ min) | 25 | $3,783 |
2022
| Return visit (30+ min) | 177 | $16,648 |
2021
| Return visit (30+ min) | 172 | $17,578 |
| Long return visit (40+ min) | 80 | $9,836 |
2020
| Return visit (30+ min) | 156 | $12,610 |
| Long return visit (40+ min) | 29 | $3,288 |
2019
| Return visit (30+ min) | 139 | $11,605 |
| Long return visit (40+ min) | 57 | $7,915 |
2018
| Return visit (30+ min) | 338 | $27,053 |
| Long return visit (40+ min) | 30 | $3,344 |
| Service | 65 | $1,260 |
| Completed early periodic screening diagnosis and treatment (epsdt) service (list in addition to code for appropriate evaluation and management service) | 21 | $355 |
Money from drug and device companies
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Boehringer Ingelheim Pharmaceuticals, Inc. · 52 Wks Eff. & Saf. Ph III in Paediatrics · 2020 | Their institution | $56,509 |
| Boehringer Ingelheim Pharmaceuticals, Inc. · 52 Wks Eff. & Saf. Ph III in Paediatrics · 2022 | Their institution | $47,415 |
| Boehringer Ingelheim Pharmaceuticals, Inc. · 52 Wks Eff. & Saf. Ph III in Paediatrics · 2021 | Their institution | $41,509 |
| Boehringer Ingelheim Pharma GmbH & Co.KG · 52 Wks Eff. & Saf. Ph III in Paediatrics · 2021 | Their institution | $18,047 |
| Boehringer Ingelheim Pharmaceuticals, Inc. · 52 Wks Eff. & Saf. Ph III in Paediatrics · 2023 | Their institution | $13,553 |
| Boehringer Ingelheim Pharma GmbH & Co.KG · 52 Wks Eff. & Saf. Ph III in Paediatrics · 2020 | Their institution | $11,731 |
| Boehringer Ingelheim Pharma GmbH & Co.KG · 52 Wks Eff. & Saf. Ph III in Paediatrics · 2019 | Their institution | $5,866 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Alogliptin Compared With Placebo in Pediatric Subjects With Type 2 Diabetes Mellitus · 2021 | Their institution | $5,200 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Alogliptin Compared With Placebo in Pediatric Subjects With Type 2 Diabetes Mellitus · 2022 | Their institution | $5,028 |
| Boehringer Ingelheim France S.A.S. · 52 Wks Eff. & Saf. Ph III in Paediatrics · 2021 | Their institution | $2,996 |
| Boehringer Ingelheim France S.A.S. · 52 Wks Eff. & Saf. Ph III in Paediatrics · 2019 | Their institution | $2,093 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Alogliptin Compared With Placebo in Pediatric Subjects With Type 2 Diabetes Mellitus · 2020 | Their institution | $1,685 |
| Boehringer Ingelheim Pharmaceuticals, Inc. · 52 Wks Eff. & Saf. Ph III in Paediatrics · 2019 | Their institution | $68 |
Professional record
- NPI
- 1912111360
- Licence
- CA A103168, OH 57010587California A103168: Current · expires 2027-08-31
- Trained
- Northwestern University Feinberg Medical School, 2005
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2080P0205X (2080P0205X); Pediatrics (208000000X)
- Mailing address
- 725 Welch Rd, Palo Alto, CA, 94304
- NPI first listed
- 2007-05-09
- NPI last updated
- 2024-04-10
- NPI record certified
- 2024-04-10
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 300 Pasteur Dr, Stanford, CA, 94305